Form4insider filings, from the source

SEC Form 4 · accession 0001193125-26-267706

Jade Biosciences, Inc. · JBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Peter Evan Harwin
Director · 10% Owner
Fairmount Funds Management LLC
Director · 10% Owner
Tomas Kiselak
Director · 10% Owner
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 4:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001798749

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F1$15.22Jun 9, 2026A34,843A—Jun 8, 2036Common Stock34,84334,843D

Explanation of responses

Remarks

Fairmount, Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest IV L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is also a Managing Member of Fairmount.